Boston Scientific (BSX)
(Delayed Data from NYSE)
$73.17 USD
-0.09 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Boston Scientific Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 1,592.00 | 698.00 | 1,041.00 | -82.00 | 4,700.00 |
Depreciation/Amortization & Depletion | 1,254.00 | 1,268.00 | 1,463.00 | 1,656.00 | 1,116.00 |
Net Change from Assets/Liabilities | -770.00 | -1,005.00 | -351.00 | 42.00 | -282.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 428.00 | 566.00 | -282.00 | -107.00 | -3,696.00 |
Net Cash From Operating Activities | 2,503.00 | 1,526.00 | 1,870.00 | 1,508.00 | 1,836.00 |
Property & Equipment | -707.00 | -576.00 | -540.00 | -364.00 | -454.00 |
Acquisition/ Disposition of Subsidiaries | -1,811.00 | -1,561.00 | -1,432.00 | 12.00 | -4,292.00 |
Investments | -89.00 | 0.00 | 279.00 | -146.00 | -149.00 |
Other Investing Activities | 32.00 | 126.00 | 97.00 | 87.00 | -147.00 |
Net Cash from Investing Activities | -2,574.00 | -2,011.00 | -1,597.00 | -411.00 | -5,041.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 182.00 | 136.00 | 110.00 | 1,526.00 | 123.00 |
Issuance (Repayment) of Debt | 0.00 | 86.00 | 0.00 | 423.00 | -3,560.00 |
Increase (Decrease) Short-Term Debt | -4.00 | -251.00 | 0.00 | -1,422.00 | 6,354.00 |
Payment of Dividends & Other Distributions | -28.00 | -55.00 | -55.00 | -28.00 | 0.00 |
Other Financing Activities | -145.00 | -463.00 | -150.00 | -205.00 | 56.00 |
Net Cash from Financing Activities | 5.00 | -548.00 | -95.00 | 293.00 | 2,973.00 |
Effect of Exchange Rate Changes | -4.00 | -9.00 | -6.00 | -2.00 | 10.00 |
Net Change In Cash & Equivalents | -70.00 | -1,042.00 | 173.00 | 1,388.00 | -222.00 |
Cash at Beginning of Period | 1,126.00 | 2,168.00 | 1,995.00 | 607.00 | 829.00 |
Cash at End of Period | 1,055.00 | 1,126.00 | 2,168.00 | 1,995.00 | 607.00 |
Diluted Net EPS | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 |
Fiscal Year End for Boston Scientific Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 1,592.00 | 1,088.00 | 584.00 | 314.00 |
Depreciation/Amortization & Depletion | NA | 1,254.00 | 941.00 | 640.00 | 285.00 |
Net Change from Assets/Liabilities | NA | -770.00 | -713.00 | -537.00 | -525.00 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 428.00 | 230.00 | 162.00 | 117.00 |
Net Cash From Operating Activities | NA | 2,503.00 | 1,546.00 | 848.00 | 190.00 |
Property & Equipment | NA | -707.00 | -440.00 | -251.00 | -108.00 |
Acquisition/ Disposition of Subsidiaries | NA | -1,811.00 | -1,018.00 | -1,018.00 | -375.00 |
Investments | NA | -89.00 | -89.00 | -73.00 | 0.00 |
Other Investing Activities | NA | 32.00 | 25.00 | 18.00 | -1.00 |
Net Cash from Investing Activities | NA | -2,574.00 | -1,521.00 | -1,324.00 | -484.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 182.00 | 165.00 | 90.00 | 63.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -4.00 | -4.00 | 37.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | -28.00 | -28.00 | -28.00 | -14.00 |
Other Financing Activities | NA | -145.00 | -143.00 | -125.00 | -118.00 |
Net Cash from Financing Activities | NA | 5.00 | -10.00 | -26.00 | -69.00 |
Effect of Exchange Rate Changes | NA | -4.00 | -8.00 | -3.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -70.00 | 7.00 | -506.00 | -363.00 |
Cash at Beginning of Period | NA | 1,126.00 | 1,126.00 | 1,126.00 | 1,126.00 |
Cash at End of Period | NA | 1,055.00 | 1,132.00 | 620.00 | 763.00 |
Diluted Net EPS | NA | 0.34 | 0.34 | 0.18 | 0.21 |